NO973685L - Multi-tumor avvikende vekstgener - Google Patents
Multi-tumor avvikende vekstgenerInfo
- Publication number
- NO973685L NO973685L NO973685A NO973685A NO973685L NO 973685 L NO973685 L NO 973685L NO 973685 A NO973685 A NO 973685A NO 973685 A NO973685 A NO 973685A NO 973685 L NO973685 L NO 973685L
- Authority
- NO
- Norway
- Prior art keywords
- genes
- aberrant growth
- growth genes
- tumor aberrant
- tumor
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000001594 aberrant effect Effects 0.000 title abstract 2
- 102000018802 High Mobility Group Proteins Human genes 0.000 abstract 1
- 101710176246 High mobility group protein Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95200390 | 1995-02-17 | ||
EP95201951A EP0727487A1 (fr) | 1995-02-17 | 1995-07-14 | Gènes de croissance aberrants de multiples tumeurs |
PCT/EP1996/000716 WO1996025493A1 (fr) | 1995-02-17 | 1996-02-19 | Genes de croissance aberrante presents dans de multiples tumeurs |
Publications (2)
Publication Number | Publication Date |
---|---|
NO973685D0 NO973685D0 (no) | 1997-08-11 |
NO973685L true NO973685L (no) | 1997-10-17 |
Family
ID=8220025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO973685A NO973685L (no) | 1995-02-17 | 1997-08-11 | Multi-tumor avvikende vekstgener |
Country Status (14)
Country | Link |
---|---|
US (3) | US6544784B1 (fr) |
EP (3) | EP0727487A1 (fr) |
JP (4) | JPH11500614A (fr) |
KR (1) | KR19980702276A (fr) |
AT (1) | ATE338114T1 (fr) |
AU (1) | AU4879096A (fr) |
CA (1) | CA2213237A1 (fr) |
CZ (1) | CZ247597A3 (fr) |
DE (2) | DE69636495T2 (fr) |
FI (1) | FI973354A (fr) |
HU (1) | HUP9800028A3 (fr) |
NO (1) | NO973685L (fr) |
PL (1) | PL321831A1 (fr) |
WO (1) | WO1996025493A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323329B1 (en) | 1995-12-21 | 2001-11-27 | Jorn Bullerdiek | Nucleic acid sequences of genes encoding high mobility group proteins |
DE19548122A1 (de) * | 1995-12-21 | 1997-06-26 | Joern Prof Dr Bullerdiek | Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben |
US6171779B1 (en) | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
WO1998050536A1 (fr) * | 1997-05-07 | 1998-11-12 | University Of Medicine & Dentistry Of New Jersey | Proteines hmgi se trouvant dans les tumeurs et l'obesite |
EP0878552A1 (fr) * | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Détection moléculaire d'aberration chromosomique |
WO1999006563A1 (fr) | 1997-07-30 | 1999-02-11 | Emory University | Nouvelle proteine de mineralisation osseuse, adn, vecteurs et systemes d'expressions |
US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
AU3516899A (en) * | 1998-05-04 | 1999-11-23 | Dako A/S | Method and probes for the detection of chromosome aberrations |
EP1077875B1 (fr) | 1998-05-05 | 2003-01-29 | Elau Elektronik Automations AG | Machine d'emballage |
IT1299583B1 (it) * | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
DE19904514A1 (de) * | 1999-02-04 | 2000-08-10 | Joern Bullerdiek | Mittel zur Prävention und/oder Behandlung von Leiomyomen |
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
EP1412754A4 (fr) * | 2001-06-27 | 2005-10-19 | Inst Medical W & E Hall | Procede et agents diagnostiques |
JP2005511770A (ja) * | 2001-12-19 | 2005-04-28 | アルケド バイオテック ゲーエムベーハー | Hmgbタンパク質およびhmgbタンパク質をコードする核酸の使用方法 |
US20030219742A1 (en) * | 2002-03-29 | 2003-11-27 | Sanjay Bhanot | Antisense modulation of HMGI-C expression |
US20040005601A1 (en) * | 2002-04-05 | 2004-01-08 | Adam Siddiqui-Jain | Methods for targeting quadruplex DNA |
US7405041B2 (en) * | 2002-08-20 | 2008-07-29 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for regulating transcription by targeting quadruplex DNA |
US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
WO2005026209A2 (fr) | 2003-09-11 | 2005-03-24 | Critical Therapeutics, Inc. | Anticorps monoclonaux diriges contre hmgb1 |
US8415315B2 (en) | 2004-05-06 | 2013-04-09 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for inhibiting the proliferation of cancer cells |
US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
EP1812065A4 (fr) | 2004-10-22 | 2009-09-02 | Medimmune Inc | Anticorps d'affinité élevée contre la hmgb1 et procédés d'utilisation |
WO2007076200A2 (fr) | 2005-11-28 | 2007-07-05 | Medimmune, Inc. | Antagonistes de hmgb1 et/ou rage et leurs procedes d'utilisation |
US8470325B2 (en) | 2007-02-15 | 2013-06-25 | Kagoshima University | Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody |
JP5366039B2 (ja) * | 2008-03-18 | 2013-12-11 | 株式会社常光 | 悪性腫瘍の予想、診断のための方法および組成物 |
US20100297649A1 (en) * | 2009-04-22 | 2010-11-25 | Oliveira Andre M | Methods and materials for detecting gene amplification |
EP2764118A1 (fr) | 2011-10-05 | 2014-08-13 | University of Bremen | Wnt4 et med12 pour l'utilisation dans le diagnostic et le traitement de maladies tumorales |
US20180127831A1 (en) * | 2015-05-21 | 2018-05-10 | Université de Montréal | Prognostic markers of acute myeloid leukemia survival |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62166897A (ja) * | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | 核内非ヒストン蛋白質に対するモノクロ−ナル抗体 |
EP0498827B1 (fr) * | 1989-11-02 | 2001-08-01 | DictyTech Pty Limited | Vecteurs de plasmide ameliores pour myxomycetes cellulaires du gene dictyostelium |
US5756307A (en) * | 1991-09-20 | 1998-05-26 | The United States Of America As Represented By The Department Of Health And Human Services | Sequence of human dopamine transporter cDNA |
US6171779B1 (en) * | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
-
1995
- 1995-07-14 EP EP95201951A patent/EP0727487A1/fr not_active Withdrawn
-
1996
- 1996-02-19 AT AT96904836T patent/ATE338114T1/de not_active IP Right Cessation
- 1996-02-19 EP EP06076468.5A patent/EP1762619B1/fr not_active Expired - Lifetime
- 1996-02-19 DE DE69636495T patent/DE69636495T2/de not_active Expired - Fee Related
- 1996-02-19 KR KR1019970705673A patent/KR19980702276A/ko not_active Application Discontinuation
- 1996-02-19 EP EP96904836A patent/EP0811061B2/fr not_active Expired - Lifetime
- 1996-02-19 CA CA002213237A patent/CA2213237A1/fr not_active Abandoned
- 1996-02-19 PL PL96321831A patent/PL321831A1/xx unknown
- 1996-02-19 DE DE0811061T patent/DE811061T1/de active Pending
- 1996-02-19 US US08/894,454 patent/US6544784B1/en not_active Expired - Fee Related
- 1996-02-19 JP JP8524678A patent/JPH11500614A/ja not_active Withdrawn
- 1996-02-19 AU AU48790/96A patent/AU4879096A/en not_active Abandoned
- 1996-02-19 HU HU9800028A patent/HUP9800028A3/hu unknown
- 1996-02-19 CZ CZ972475A patent/CZ247597A3/cs unknown
- 1996-02-19 WO PCT/EP1996/000716 patent/WO1996025493A1/fr active IP Right Grant
-
1997
- 1997-08-11 NO NO973685A patent/NO973685L/no not_active Application Discontinuation
- 1997-08-15 FI FI973354A patent/FI973354A/fi unknown
-
2003
- 2003-01-28 US US10/352,615 patent/US20030190285A1/en not_active Abandoned
-
2006
- 2006-09-27 JP JP2006262093A patent/JP2007082549A/ja not_active Withdrawn
-
2007
- 2007-05-25 US US11/807,330 patent/US20110318834A1/en not_active Abandoned
- 2007-11-08 JP JP2007290671A patent/JP2008099698A/ja active Pending
-
2009
- 2009-07-27 JP JP2009173847A patent/JP2009254378A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NO973685D0 (no) | 1997-08-11 |
EP0727487A1 (fr) | 1996-08-21 |
AU4879096A (en) | 1996-09-04 |
US20110318834A1 (en) | 2011-12-29 |
HUP9800028A3 (en) | 2001-02-28 |
EP0811061A1 (fr) | 1997-12-10 |
JP2008099698A (ja) | 2008-05-01 |
EP1762619A3 (fr) | 2007-05-09 |
DE69636495D1 (de) | 2006-10-12 |
US6544784B1 (en) | 2003-04-08 |
EP0811061B2 (fr) | 2010-07-21 |
US20030190285A1 (en) | 2003-10-09 |
EP1762619A2 (fr) | 2007-03-14 |
JP2007082549A (ja) | 2007-04-05 |
FI973354A0 (fi) | 1997-08-15 |
WO1996025493A1 (fr) | 1996-08-22 |
CA2213237A1 (fr) | 1996-08-22 |
JP2009254378A (ja) | 2009-11-05 |
DE69636495T2 (de) | 2007-05-24 |
HUP9800028A2 (hu) | 1998-04-28 |
EP0811061B1 (fr) | 2006-08-30 |
ATE338114T1 (de) | 2006-09-15 |
FI973354A (fi) | 1997-10-16 |
PL321831A1 (en) | 1997-12-22 |
EP1762619B1 (fr) | 2013-06-26 |
JPH11500614A (ja) | 1999-01-19 |
KR19980702276A (ko) | 1998-07-15 |
CZ247597A3 (cs) | 1998-07-15 |
DE811061T1 (de) | 2002-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO973685L (no) | Multi-tumor avvikende vekstgener | |
NZ316787A (en) | Methods and compositions for the selective modification of nucleic acids | |
AU7489687A (en) | Translation of mrna | |
NO872757D0 (no) | Alkynylaminonukleotider og fremgangsmaate for fremstilling av disse. | |
DK0759927T3 (da) | Pteridinnucleotidanaloger som fluorescerende DNA prober | |
ATE366806T1 (de) | Dna-molekül, herstellung und verwendung in der gentherapie | |
TR200700740T2 (tr) | Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler | |
FR2637612B1 (fr) | Sequences de nucleotides codant pour une proteine a activite ureasique | |
DE60327786D1 (de) | Kdr-peptide und diese enthaltende impfstoffe | |
ATE259828T1 (de) | Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel | |
DK0733109T3 (da) | BMP-12, BMP-13 og seneinducerende præparater dermed | |
HUP9900018A1 (hu) | Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására | |
ATE449850T1 (de) | Mutanten von flt3-l und ihre verwendungen | |
WO1997020933A3 (fr) | VARIANTES MUTATIONNELLES DE PROTEINES DE GENES Ob CHEZ LES MAMMIFERES | |
ATE190352T1 (de) | Dorsalgewebe beeinflussender faktor und zusammensetzungen | |
MXPA03006984A (es) | Secuencia de nucleotidos que median la fertilidad masculina y metodo de uso de la misma. | |
ATE88500T1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
DE69816467D1 (de) | Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung | |
ATE385517T1 (de) | Interferon ähnliche moleküle, und deren verwendungen | |
HUP9802681A1 (hu) | Onkogénnel vagy vírussal szabályozott expressziós rendszerek | |
MX9806041A (es) | Proteina purificada sr-p70. | |
ATE263239T1 (de) | Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2) | |
AU6144294A (en) | Plant virus resistance conferring polyribozyme and resistant plants producing same | |
RU93031156A (ru) | Способ получения плазмид, кодирующих химерный белок с последовательностью соматостатина, штамм бактерий escherichia coli - продуцент этого белка, белок, полученный в этом штамме, содержащий фрагмент ацетилтрансферазы, спейсер и иммуногенный соматостатин | |
DK0688786T3 (da) | Hydrazino- og hydroxyamino-14beta-hydroxyandrostanderivater med aktivitet på det cardiovaskulære system, fremgangsmåder til deres fremstilling og farmaceutiske præparater indeholdende disse. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |